{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T06:01:38Z","timestamp":1791698498702,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.esmogo.2025.100209","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T19:55:03Z","timestamp":1753214103000},"page":"100209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"PA","title":["Management of oligometastatic anal cancer\u2014a literature review and a proposed treatment algorithm"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2457-3175","authenticated-orcid":false,"given":"A.","family":"Johnsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.L.","family":"Wind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7419-6750","authenticated-orcid":false,"given":"M.P.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.esmogo.2025.100209_bib1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/0284186X.2022.2048069","article-title":"Anal cancer in Sweden 2015-2019. Implementation of guidelines, structural changes, national registry and early results","volume":"61","author":"Johnsson","year":"2022","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100209_bib2","first-page":"e96","article-title":"Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016","volume":"18","author":"Guren","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"16","key":"10.1016\/j.esmogo.2025.100209_bib3","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"J Am Med Assoc"},{"issue":"16","key":"10.1016\/j.esmogo.2025.100209_bib4","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmogo.2025.100209_bib5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmogo.2025.100209_bib6","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2025.100209_bib7","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmogo.2025.100209_bib8","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Rao","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmogo.2025.100209_bib9","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/sj.bjc.6603033","article-title":"Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies","volume":"94","author":"Simmonds","year":"2006","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100209_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-5223(97)70397-0","article-title":"Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases","volume":"113","author":"Pastorino","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100209_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.esmogo.2025.100209_bib12","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1200\/JCO.22.01482","article-title":"Oligometastases: emerging evidence","volume":"40","author":"Liu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100209_bib13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): extended long-term outcomes","volume":"114","author":"Harrow","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmogo.2025.100209_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"issue":"15","key":"10.1016\/j.esmogo.2025.100209_bib15","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.3390\/cancers15153890","article-title":"Hepatic metastasectomy in squamous cell carcinoma of the anal canal: a case series of a curative approach","volume":"15","author":"Rogers","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100209_bib16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jso.27539","article-title":"Long-term overall survival in patients undergoing liver resection for metastatic anal squamous cell carcinoma","volume":"129","author":"Lo","year":"2024","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.esmogo.2025.100209_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.918271","article-title":"Long-term disease control after locoregional pelvic chemoradiation in patients with advanced anal squamous cell carcinoma","volume":"12","author":"Grave","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100209_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/0284186X.2021.1999497","article-title":"Definitive therapy for squamous cell carcinoma of the anus with synchronous metastases - a report from the Danish Anal Cancer Group","volume":"61","author":"Wind","year":"2022","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100209_bib19","doi-asserted-by":"crossref","first-page":"zrab060","DOI":"10.1093\/bjsopen\/zrab060","article-title":"Liver resection and ablation for squamous cell carcinoma liver metastases","volume":"5","author":"Engstrand","year":"2021","journal-title":"BJS Open"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100209_bib20","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.amjsurg.2020.08.016","article-title":"Role of metastasectomy for liver metastasis in stage IV anal cancer","volume":"221","author":"Goldner","year":"2021","journal-title":"Am J Surg"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100209_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/jso.25320","article-title":"Multimodality treatment of oligometastatic anal squamous cell carcinoma: a case series and literature review","volume":"119","author":"Sclafani","year":"2019","journal-title":"J Surg Oncol"},{"issue":"9","key":"10.1016\/j.esmogo.2025.100209_bib22","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.21873\/anticanres.12870","article-title":"Image-guided interstitial brachytherapy in the management of metastasized anal squamous cell carcinoma","volume":"38","author":"Heinze","year":"2018","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.esmogo.2025.100209_bib23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/DCR.0000000000000827","article-title":"Multimodal therapy of squamous cell carcinoma of the anus with distant metastasis: a single-institution experience","volume":"60","author":"Evesque","year":"2017","journal-title":"Dis Colon Rectum"},{"issue":"11","key":"10.1016\/j.esmogo.2025.100209_bib24","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.ejso.2017.09.006","article-title":"Long term outcome after resection of liver metastases from squamous cell carcinoma","volume":"43","author":"Omichi","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"22","key":"10.1016\/j.esmogo.2025.100209_bib25","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.18632\/oncotarget.2563","article-title":"The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal","volume":"5","author":"Eng","year":"2014","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.esmogo.2025.100209_bib26","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1245\/s10434-007-9467-8","article-title":"Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis","volume":"14","author":"Pawlik","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100209_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13014-020-01567-7","article-title":"Patterns of recurrence in anal cancer: a detailed analysis","volume":"15","author":"Nilsson","year":"2020","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100209_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijrobp.2018.04.076","article-title":"Extended-field chemoradiation therapy for definitive treatment of anal canal squamous cell carcinoma involving the para-aortic lymph nodes","volume":"102","author":"Holliday","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100209_bib29","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ijrobp.2008.11.021","article-title":"Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement","volume":"75","author":"Hodges","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmogo.2025.100209_bib30","article-title":"Prophylactic extended-field irradiation in patients with cervical cancer: a literature review","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2025.100209_bib31","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/0284186X.2023.2240490","article-title":"Nordic anal cancer (NOAC) group consensus guidelines for risk-adapted delineation of the elective clinical target volume in anal cancer","volume":"62","author":"Nilsson","year":"2023","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100209_bib32","first-page":"287","article-title":"The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer","volume":"71","author":"Olawaiye","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"10.1016\/j.esmogo.2025.100209_bib33","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmogo.2025.100209_bib34","doi-asserted-by":"crossref","first-page":"S1217","DOI":"10.1016\/j.annonc.2024.08.2262","article-title":"POD1UM\/InterAACT 2: phase III study of retifanlimab with carboplatin-paclitaxel in patients with inoperable locally recurrent or metastatic squamous cel carcinoma of the anal cancer not previously treated with systemic chemotherapy","volume":"35","author":"Rao","year":"2024","journal-title":"Ann Oncol"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825000780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825000780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:30:13Z","timestamp":1784557813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819825000780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":34,"alternative-id":["S2949819825000780"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100209","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of oligometastatic anal cancer\u2014a literature review and a proposed treatment algorithm","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100209"}}